

Title (en)
METHOD FOR IDENTIFYING ALZHEIMER'S DISEASE THERAPEUTICS USING TRANSGENIC ANIMAL MODELS

Title (de)
METHODE ZUR IDENTIFIZIERUNG VON ARZNEIMITTELN GEGEN DER ALZHEIMER KRANKHEIT MITTELS TRANSGENER TIERMODELLE

Title (fr)
PROCEDE D'IDENTIFICATION DE THERAPIES DE LA MALADIE D'ALZHEIMER A L'AIDE DE MODELES ANIMAUX TRANSGENIQUES

Publication
EP 0832205 A1 19980401 (EN)

Application
EP 96921420 A 19960607

Priority

- US 9609679 W 19960607
- US 48601895 A 19950607
- US 48653895 A 19950607

Abstract (en)
[origin: WO9640895A1] The construction of transgenic animal models for testing potential treatments for Alzheimer's disease are described. The models are characterized by pathology similar to that observed in Alzheimer's disease, based on expression of all three forms of the beta -amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the A beta region. The APP gene constructs are prepared using the human platelet derived growth factor B(PDGF-B) chain gene promoter, or other promoters able to express A DOLLAR (b) or mutant forms APP at a high level in transgenic animal brain tissue. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP and beta -amyloid peptide, neuropathology, and behavioral alterations.

IPC 1-7
C12N 15/00; **C12N 15/12**; **C12N 15/62**; **C07K 14/47**; **A01K 67/027**; **G01N 33/50**

IPC 8 full level
A01K 67/027 (2006.01); **A61K 45/00** (2006.01); **A61P 25/28** (2006.01); **C07K 14/47** (2006.01); **C12N 15/09** (2006.01); **C12N 15/85** (2006.01); **C12Q 1/02** (2006.01)

CPC (source: EP)
A01K 67/0275 (2013.01); **A01K 67/0278** (2013.01); **A61P 25/28** (2017.12); **C07K 14/4711** (2013.01); **C12N 15/8509** (2013.01); **A01K 2207/15** (2013.01); **A01K 2217/00** (2013.01); **A01K 2217/05** (2013.01); **A01K 2227/105** (2013.01); **A01K 2267/0312** (2013.01); **C07K 2319/02** (2013.01)

Citation (search report)
See references of WO 9640895A1

Cited by
US7569040B2

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9640895 A1 19961219; AU 6264996 A 19961230; CA 2221986 A1 19961219; EP 0832205 A1 19980401; JP 2001517065 A 20011002

DOCDB simple family (application)
US 9609679 W 19960607; AU 6264996 A 19960607; CA 2221986 A 19960607; EP 96921420 A 19960607; JP 50194697 A 19960607